Dose Escalation Study of Bendamustine Based Conditioning Regime (Bace-Bendamustine, Cytarabine, Cyclophosphamide and Etoposide) in Patients with Lymphoma Undergoing Autologous Stem Cell Transplant
ثبت نشده
چکیده
Autologous Stem Cell Transplantation (ASCT) is a standard of care in relapsed diffuse large B-cell lymphoma (DLBCL) and other lymphoproliferative disorders including relapsed Hodgkin’s disease, mantle or T-cell lymphoma. Carmustine, etoposide, ARA-C, melphalan (BEAM) [1], lomustine, etoposide, ARA-C, melphalan (LEAM) and lomustine, ARA-C, cyclophosphamide, etoposide (LACE) are commonly used condition in regimes. However, Carmustine and lomustine are associated with interstitial pneumonia (2 to 20%) and increased risk of morbidity and mortality. Therefore a less toxic regimen might improve the results in relapsed lymphoma patients.
منابع مشابه
Z-BeEAM (Ibritumomab tiuxetan, Bendamustine, Etoposide, Cytarabine, Melphalan) before autologous stem cell transplantation is safe and efficient for refractory large B-cell lymphoma
BACKGROUND Refractory or relapsed large B-cells lymphoma are usually treated with a high dose chemotherapy regimen followed by an autolougous stem cells transplantation. BEAM (carmustine, etoposide, cytarabine, melphalan) or more recently Z-BEAM (ibritumomab tiuxetan and BEAM) are commonly used regimens, but recently carmustine availability became difficult. The purpose of this study was to eva...
متن کاملBeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients.
We designed a phase 1-2 study to evaluate the safety and the efficacy of increasing doses of bendamustine (160 mg/m², 180 mg/m², and 200 mg/m² given on days -7 and -6) coupled with fixed doses of etoposide, cytarabine, and melphalan (BeEAM regimen) as the conditioning regimen to autologous stem cell transplantation for resistant/relapsed lymphoma patients. Forty-three patients (median age, 47 y...
متن کاملThe place of transplantation in mantle cell lymphoma.
Mantle cell lymphoma (MCL) is an uncommon non-Hodgkin lymphoma with a heterogeneous natural history. Significant strides have been made in the management of MCL. Clinical follow-up exceeds a decade with long-term remission durations in some patients. Modern induction strategies employ rituximab; a cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-like backbone; and cytarabine (i...
متن کاملCurrent and emerging therapies in mantle cell lymphoma.
Mantle Cell Lymphoma, characterized by the t(11;14)(q13; q32) chromosomal translocation and cyclin D1 expression, remains one of the most challenging lymphoma subtypes to treat. Therapy can be divided into treatment modalities for younger, stem cell transplant (SCT)-eligible patients vs older, SCT-ineligible patients. For clinically fit patients younger than 60-65 years of age we recommend cyta...
متن کاملSingle-Agent Pixantrone as a Bridge to Autologous Stem Cell Transplantation in a Patient with Refractory Diffuse Large B-Cell Lymphoma.
Aggressive non-Hodgkin lymphoma is associated with poor long-term survival after relapse or resistance to chemotherapy. We report a case of aggressive non-Hodgkin lymphoma refractory to first-line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) and second-line R-DHAP (rituximab, dexamethasone, cytarabine, and cisplatin) chemotherapy treatments. The patient achieve...
متن کامل